Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Amortization of Deferred Charges (2024 - 2025)

Ensysce Biosciences (ENSC) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $300000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 74.39% to $300000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $300000.0, a N/A change, with the full-year FY2024 number at $1.2 million, up 267.07% from a year prior.
  • Amortization of Deferred Charges was $300000.0 for Q1 2025 at Ensysce Biosciences, up from $25735.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.2 million in Q1 2024 to a low of $25735.0 in Q2 2024.